{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:55:20Z","timestamp":1790920520610,"version":"4.1.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thrombocytopenia during immune checkpoint inhibitor treatment in lung cancer may be coded as immune, marrow suppression, coagulation, or non-specific. We tested whether coding-defined report phenotypes differed across co-reported treatment contexts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed FAERS (2015Q1\u20132026Q2) and JADER through Japanese fiscal 2025Q4 (31 March 2026). Strict primary lung cancer reports were grouped as ICI without chemotherapy (C1), ICI plus chemotherapy (C2), or chemotherapy without ICI (C3). Firth models compared mutually exclusive immune-like and marrow-like anchors. Complementary analyses evaluated the broad cohort, treatment date compatibility, C3 small-cell influence, phenotype variants, onset windows, treatment-variable ablation in elastic-net report phenotype models, and a 120-report random stratified blinded review with independent ratings, third-person adjudication, inverse-selection weighting, and bootstrap uncertainty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      FAERS included 1,362 immune-like or marrow-like anchors. Relative to C1, adjusted odds ratios (ORs) for immune-like versus marrow-like phenotype were 0.111 (95% CI, 0.069\u20130.173) in C2 and 0.014 (0.006\u20130.029) in C3; C3 was exploratory because only eight reports were immune-like. In 2,835 broad cohort reports, adjusted immune-like composition was 13.0% (95% bootstrap interval, 11.0%\u201315.1%) in C1 and 4.7% (3.4%\u20136.2%) in C2. Treatment date and stricter phenotype analyses were directionally consistent. JADER reproduced the C2 versus C1 direction but showed calibration shift; treatment-variable ablation reduced cross-database discrimination. Reviewers agreed on 111\/120 reports (92.5%; 95% CI, 87.5%\u201396.7%; Cohen\u2019s\n                      <jats:italic>\u03ba<\/jats:italic>\n                      , 0.897; Gwet\u2019s AC1, 0.901). In the locked 927-report frame, design-weighted final categories were 23.4% immune probable, 37.3% immune possible, 13.6% indeterminate, and 25.8% non-immune probable. Among 100 determinate reports, weighted AUROC was 0.892 (0.827\u20130.948), PR-AUC 0.956 (0.922\u20130.982), and calibration-in-the-large intercept 2.054 (1.707\u20132.432), indicating underprediction.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Coding-defined thrombocytopenia report composition differed across treatment contexts. Blinded review supported reproducible structured category assignment and score-based report ordering, while calibration shift and treatment-variable ablation defined important limits. Findings support pharmacovigilance case prioritization and hypothesis generation, not clinical diagnosis, incidence estimation, patient-level etiologic attribution, or causal inference.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1970912","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:35:23Z","timestamp":1790919323000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment context is associated with thrombocytopenia report phenotypes in lung cancer: an active-comparator analysis of FAERS and JADER"],"prefix":"10.3389","volume":"17","author":[{"given":"Fan","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Leshan People\u2019s Hospital","place":["Leshan, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinliang","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Leshan People\u2019s Hospital","place":["Leshan, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhineng","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Leshan People\u2019s Hospital","place":["Leshan, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongchen","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Leshan People\u2019s Hospital","place":["Leshan, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00825","article-title":"Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO living guideline","volume":"40","author":"Singh","year":"2022","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2169531","article-title":"Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis","volume":"19","author":"Lu","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.21037\/atm-21-1423","article-title":"Immune checkpoint inhibitors for treatment of small-cell lung cancer: a systematic review and meta-analysis","volume":"9","author":"Niu","year":"2021","journal-title":"Ann Transl Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN Guidelines\u00ae Insights: Management of immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00277-021-04690-x","article-title":"Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review","volume":"101","author":"Ghanem","year":"2022","journal-title":"Ann Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26273","article-title":"Immune-related hematologic adverse events in the context of immune checkpoint inhibitor therapy","volume":"96","author":"Saliba","year":"2021","journal-title":"Am J Hematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/CJI.0000000000000390","article-title":"Management and outcomes of hematological immune-related adverse events: systematic review and meta-analysis","volume":"45","author":"Wilson","year":"2022","journal-title":"J Immunother"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2026.103121","article-title":"Hematological immune-related adverse events associated with checkpoint inhibitors","volume":"145","author":"Janson","year":"2026","journal-title":"Cancer Treat Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025031449","article-title":"Immune thrombocytopenia in patients treated with immune checkpoint inhibitors","volume":"147","author":"Leaf","year":"2026","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111606","article-title":"PD-1\/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review","volume":"129","author":"Moore","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"23699","DOI":"10.1038\/s41598-024-75271-x","article-title":"Signal detection of immune thrombocytopenia associated with immune checkpoint inhibitors","volume":"14","author":"Mo","year":"2024","journal-title":"Sci Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1407894","article-title":"Association of thrombocytopenia with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis based on the data from FDA adverse event reporting system database","volume":"15","author":"Liu","year":"2024","journal-title":"Front Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00262-026-04380-5","article-title":"Hematological toxicities and thrombosis risk associated with immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2024","volume":"75","author":"Hou","year":"2026","journal-title":"Cancer Immunol Immunother"},{"key":"B17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.14740\/jh1090","article-title":"Incidence and risk of hematological adverse events associated with immune checkpoint inhibitors: a systematic literature review and meta-analysis","volume":"12","author":"Ohashi","year":"2023","journal-title":"J Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1924053","article-title":"Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia","volume":"14","author":"Al-Samkari","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jtha.2023.09.031","article-title":"Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH Subcommittee on Hemostasis and Malignancy","volume":"22","author":"Soff","year":"2024","journal-title":"J Thromb Haemost"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279512","article-title":"Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic Malignancies","volume":"107","author":"Kuter","year":"2022","journal-title":"Haematologica"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1634688","article-title":"Cancer treatment-induced thrombocytopenia: diagnosis, mechanisms and management","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17172","article-title":"Disseminated intravascular coagulation: epidemiology, biomarkers, and management","volume":"192","author":"Adelborg","year":"2021","journal-title":"Br J Haematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01423-7","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"B26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","article-title":"Bias reduction of maximum likelihood estimates","volume":"80","author":"Firth","year":"1993","journal-title":"Biometrika"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-024-01472-w","article-title":"Clinical characteristics, treatment, and outcomes of nivolumab induced immune thrombocytopenia","volume":"42","author":"Peng","year":"2024","journal-title":"Invest New Drugs"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17387","article-title":"Immune thrombocytopenia after immune checkpoint inhibitor therapy","volume":"193","author":"Amanam","year":"2021","journal-title":"Br J Haematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790051","article-title":"Immune thrombocytopenia induced by immune checkpoint inhibitrs in lung cancer: case report and literature review","volume":"12","author":"Xie","year":"2021","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-745","article-title":"Immune thrombocytopenia in a small cell lung cancer patient treated with atezolizumab: a case report","volume":"11","author":"Qiu","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S468921","article-title":"Successful treatment of steroid-refractory immune thrombocytopenia in a patient developing multiple myeloma while on immune checkpoint inhibitor therapy for lung cancer: a case report","volume":"15","author":"Hayashi","year":"2024","journal-title":"J Blood Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/ph15050557","article-title":"Hematological and extra-hematological autoimmune complications after checkpoint inhibitors","volume":"15","author":"Fattizzo","year":"2022","journal-title":"Pharm (Basel)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjon.2024.100549","article-title":"Updates and emerging trends in the management of immune-related adverse events associated with immune checkpoint inhibitor therapy","volume":"11","author":"La-Beck","year":"2024","journal-title":"Asia Pac J Oncol Nurs"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101139","article-title":"Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists","volume":"63","author":"Al-Samkari","year":"2024","journal-title":"Blood Rev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.20037","article-title":"Chemotherapy-induced thrombocytopenia: modern diagnosis and treatment","volume":"206","author":"Song","year":"2025","journal-title":"Br J Haematol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101257","article-title":"Application of thrombopoietic agents in cancer therapy-induced thrombocytopenia: a comprehensive review","volume":"70","author":"Mei","year":"2025","journal-title":"Blood Rev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32080455","article-title":"Understanding chemotherapy-induced thrombocytopenia: implications for gastrointestinal cancer treatment","volume":"32","author":"Peshin","year":"2025","journal-title":"Curr Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40560-023-00672-5","article-title":"The pathophysiology, diagnosis, and management of sepsis-associated disseminated intravascular coagulation","volume":"11","author":"Iba","year":"2023","journal-title":"J Intensive Care"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/ams2.843","article-title":"Sepsis-induced disseminated intravascular coagulation: an international estrangement of disease concept","volume":"10","author":"Ushio","year":"2023","journal-title":"Acute Med Surg"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/cells12172120","article-title":"Pathophysiology of disseminated intravascular coagulation in sepsis: a clinically focused overview","volume":"12","author":"Unar","year":"2023","journal-title":"Cells"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15802","article-title":"Considerations on the use of different comparators in pharmacovigilance: a methodological review","volume":"89","author":"Gravel","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15178","article-title":"Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: an example using sodium\/glucose cotransporter 2 inhibitors","volume":"89","author":"Alkabbani","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70102","article-title":"Masking in active comparator designs in pharmacovigilance: a retrospective bias analysis on the spontaneous reporting of thiazolidinediones and cardiovascular events","volume":"34","author":"Bai","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2219892","article-title":"An overview of methodological flaws of real-world studies investigating drug safety in the post-marketing setting","volume":"22","author":"Crisafulli","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2024.1497116","article-title":"Influence of differential source patterns in the detection of signals of disproportionate reporting for PARP inhibitors","volume":"4","author":"Mestres","year":"2024","journal-title":"Front Drug Saf Regul"},{"key":"B47","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12874-022-01801-8","article-title":"Methodological guidance for the evaluation and updating of clinical prediction models: a systematic review","volume":"22","author":"Binuya","year":"2022","journal-title":"BMC Med Res Methodol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/sim.9921","article-title":"Calibrating machine learning approaches for probability estimation: a comprehensive comparison","volume":"42","author":"Ojeda","year":"2023","journal-title":"Stat Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/sim.9025","article-title":"Minimum sample size for external validation of a clinical prediction model with a binary outcome","volume":"40","author":"Riley","year":"2021","journal-title":"Stat Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2023.341532","article-title":"The importance of choosing a proper validation strategy in predictive models. A tutorial with real examples","volume":"1275","author":"Lopez","year":"2023","journal-title":"Anal Chim Acta"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1516449","article-title":"Safety evaluation of irinotecan: a real-world disproportionality analysis using FAERS and JADER databases during the time period 2004-2024","volume":"16","author":"Lou","year":"2025","journal-title":"Front Pharmacol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103160","article-title":"Disproportionality analysis of interstitial lung disease associated with novel antineoplastic agents during breast cancer treatment: a pharmacovigilance study","volume":"82","author":"Zhu","year":"2025","journal-title":"EClinicalMedicine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1970912\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:35:23Z","timestamp":1790919323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1970912\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2026.1970912"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1970912","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"article-number":"1970912"}}